高剂量凝血因子XIII在体外及大鼠失血性休克模型中有效止血创伤相关凝血病
本研究探讨凝血因子XIII(FXIII)对创伤相关凝血病(TAC)的作用。体外实验评估不同剂量FXIII(3.6–32.4 IU/mL)对组织型纤溶酶原激活物诱导的纤溶亢进及稀释性凝血病合并纤溶亢进的影响,用旋转血栓弹力图(ROTEM)和Sonoclot分析凝血状态。体内实验用大鼠肝创伤模型评估高剂量FXIII(300 IU/kg)对严重凝血病的作用,测量生存时间和腹腔出血量。结果显示高剂量FXIII显著改善血凝块强度、增加抗纤溶能力,并剂量依赖性增强血小板功能;与对照组相比,FXIII显著减少总出血量并延长生存时间。组织学检查未发现FXIII的不良反应。
要点
- 体外实验中,高剂量FXIII(3.6–32.4 IU/mL)显著改善血凝块强度并增加对纤溶亢进的抵抗,经ROTEM确认。
- Sonoclot显示FXIII以剂量依赖性方式显著增强血小板功能。
- 大鼠模型中,FXIII组(300 IU/kg)与对照组相比总出血量显著减少(32.6 ± 5.5 vs 108.9 ± 11.4 mL/kg,p < 0.001)。
- 大鼠模型中,FXIII组生存时间较对照组显著延长(120分钟 vs 26.0 ± 8.8分钟,p < 0.001)。
- FXIII组ROTEM参数及Sonoclot血小板功能较对照组显著改善,组织学检查未发现FXIII的不良反应。
适用人群与场景
- 严重创伤患者,体外实验针对组织型纤溶酶原激活物诱导的纤溶亢进及稀释性凝血病合并纤溶亢进;体内实验为大鼠肝创伤模型,观察到类似TAC的凝血病。
处置流程与药物剂量
- 体外实验使用FXIII剂量范围为3.6–32.4 IU/mL;体内大鼠实验使用高剂量FXIII 300 IU/kg。
研究设计与关键结果
- 研究类型为人体体外实验及大鼠体内实验研究;体外实验评估FXIII对纤溶亢进及稀释性凝血病合并纤溶亢进的作用,体内实验用大鼠肝创伤模型评估高剂量FXIII(300 IU/kg)对严重凝血病的作用。
- 体外实验中,高剂量FXIII显著改善血凝块强度并增加对纤溶亢进的抵抗,经ROTEM确认;Sonoclot显示FXIII剂量依赖性显著增强血小板功能。
- 大鼠模型中,FXIII组与对照组相比总出血量显著减少(32.6 ± 5.5 vs 108.9 ± 11.4 mL/kg,p < 0.001),生存时间显著延长(120分钟 vs 26.0 ± 8.8分钟,p < 0.001)。
- 大鼠模型中,FXIII组ROTEM参数及Sonoclot血小板功能较对照组显著改善;组织学检查未发现FXIII的不良反应。
证据类型、等级与局限
- 证据类型:人体体外实验及大鼠体内实验研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为高剂量FXIII治疗对伴有创伤相关凝血病的严重创伤具有显著临床影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma-associated coagulopathy (TAC) is an early and primary complication in severe trauma patients. Factor XIII (FXIII) is reported to stabilize a clot in the late phase of the coagulation cascade. The goal of this study was to investigate whether the administration of FXIII improves the condition of TAC both in vitro and in vivo.
METHODS: We evaluated the effects of different doses, including a very high dose of FXIII (3.6-32.4 IU/mL) on tissue-plasminogen activator-induced hyperfibrinolysis and the combined condition of dilutional coagulopathy and tissue-plasminogen activator-induced hyperfibrinolysis in vitro. The coagulation status was analyzed by rotational thromboelastometry (ROTEM) and Sonoclot. Then, we evaluated the effect of high-dose FXIII (300 IU/kg) for severe coagulopathy in vivo using a rat liver trauma model in which coagulopathy similar to TAC was observed. Survival time and the amount of intra-abdominal bleeding of rats were measured, and a coagulation test was also performed. Histologic evaluations of rats' lung and kidney after FXIII administration were completed.
RESULTS: High-dose FXIII significantly improved clot strength as well as increased resistance to hyperfibrinolysis in vitro which was confirmed by ROTEM. Platelet function on Sonoclot was significantly increased by FXIII in a dose-dependent manner. Factor XIII significantly decreased the total amount of bleeding and prolonged the survival time compared to control (control vs FXIII: 108.9 ± 11.4 vs 32.6 ± 5.5 mL/kg; p < 0.001; 26.0 ± 8.8 vs 120 minutes, p < 0.001) in a rat model. Rotational thromboelastometry parameters and platelet function on Sonoclot were significantly improved in the FXIII (+) group compared to control. No adverse effects of FXIII were detected histologically.
CONCLUSION: Factor XIII not only generated stable clot resistance to hyperfibrinolysis but also enhanced platelet function by facilitating clot retraction. High-dose FXIII administration therapy has significant clinical impact for severe trauma accompanied with TAC.
STUDY TYPE: Human in vitro and rat in vivo experimental study.
参考来源
- Nagashima F, Inoue S, Koami H, et al. High-dose Factor XIII administration induces effective hemostasis for trauma-associated coagulopathy (TAC) both in vitro and in rat hemorrhagic shock in vivo models. J Trauma Acute Care Surg. 2018. PMID: 29851904. doi:10.1097/TA.0000000000001998
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。